Literature DB >> 21914268

[Long-term studies on clinical therapeutic efficiency of posterior scleral reinforcement surgery].

Xiu-duo Liu1, Jia-hua Lü, Ren-yuan Chu.   

Abstract

OBJECTIVE: To assess the safety and efficiency of posterior scleral reinforcement surgery by analyzing data collected for more than ten years after the surgery.
METHODS: Sixteen patients (32 eyes) with high myopia who underwent scleral reinforcement were followed up for more than ten years (10 to 13 years).
RESULTS: Best corrected visual acuity was stable (t = 0.26, P > 0.05). The average axial elongation was 0.056 mm per year postoperation after surgery. The ratio of choroidal neovascularization in the operation group was 3.1% (1/32).
CONCLUSIONS: Posterior scleral reinforcement is a safe and effective. This procedure can prevent the development of choroidal neovascularization in high myopia. A control study with a larger group of cases as well as related basic is still required.

Entities:  

Mesh:

Year:  2011        PMID: 21914268

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  4 in total

1.  Posterior scleral reinforcement for the treatment of pathological myopia.

Authors:  Xiu-Juan Li; Xiao-Peng Yang; Qiu-Ming Li; Yu-Ying Wang; Yuan Wang; Xiao-Bei Lyu; Heng Jia
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

2.  Application of optical coherence tomography angiography in assessment of posterior scleral reinforcement for pathologic myopia.

Authors:  Jing Mo; An-Li Duan; Szy-Yann Chan; Xue-Fei Wang; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

Review 3.  Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia.

Authors:  Sangeethabalasri Pugazhendhi; Balamurali Ambati; Allan A Hunter
Journal:  Clin Ophthalmol       Date:  2020-03-18

4.  Myopic Macular Retinoschisis in Teenagers: Clinical Characteristics and Spectral Domain Optical Coherence Tomography Findings.

Authors:  Chuan-Bin Sun; Yong-Sheng You; Zhe Liu; Lin-Yan Zheng; Pei-Qing Chen; Ke Yao; An-Quan Xue
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.